CIR-NK cells (HLA-G target)
Refractory leukemias and solid tumors
Pre-clinicalActive
Key Facts
Indication
Refractory leukemias and solid tumors
Phase
Pre-clinical
Status
Active
Company
About NKILT Therapeutics
NKILT Therapeutics is an early-stage biotech pioneering a unique approach to cell therapy by targeting the HLA-G checkpoint via engineered NK cells. Its core CIR™ platform is designed to leverage natural receptor binding for specificity and enhanced signaling, with potential application across over 50% of cancers. Founded in 2020/2021 and based in Cambridge, MA, the company is in pre-clinical development, building a team with deep oncology and cell therapy experience to advance its off-the-shelf therapies toward the clinic.
View full company profile